Country: Australia
Bahasa: Inggeris
Sumber: APVMA (Australian Pesticides and Veterinary Medicines Authority)
GNRF - PROTEIN CONJUGATE; THIOMERSAL
ZOETIS AUSTRALIA PTY LTD
GnRF-protein conjugate(200ug/mL)
PARENTERAL LIQUID/SOLUTION/SUSPENSION
GNRF - PROTEIN CONJUGATE BIOLOGICAL-PROTEIN Active 200.0 ug/ml; THIOMERSAL MERCURY Other 0.1 mg/ml
1 x 10mL; 1 x 1mL; 10 x 1mL; 20 x 1mL
VM - Veterinary Medicine
ZOETIS AUSTRALIA
HORSE FILLY (YOUNG FEMALE) | HORSE MARE (FEMALE) | FEMALE HORSE | HORSE - YOUNG FEMALE
ENDOCRINE SYSTEM
EQUINE OESTRUS CYCLE | CTRL OF OESTRUS REL.BEHAVIOUR
Poison schedule: 4; Withholding period: WHP: Meat: Nil.; Host/pest details: HORSE FILLY (YOUNG FEMALE): [EQUINE OESTRUS CYCLE]; HORSE MARE (FEMALE): [EQUINE OESTRUS CYCLE]; Poison schedule: 4; Withholding period: ; Host/pest details: HORSE FILLY (YOUNG FEMALE): [EQUINE OESTRUS CYCLE]; HORSE MARE (FEMALE): [EQUINE OESTRUS CYCLE]; An aid in the control of oestrus and oestrus related behaviour in fillies and mares not intended for breeding.Do not use this product in horses intended for breeding, or in pregnant mares.
Registered
2023-07-01
APPENDIX 2 AUSTRALIAN GOVERNMENT AUSTRALIAN PESTICIDES AND VETERINARY MEDICINES AUTHORITY TEMPLATE FOR RELEVANT LABEL PARTICULARS (RLPS) (VETERINARY PRODUCTS) Select appropriate: CL New Product (include all applicable RLPs) OR 0 Variation (highlight instructions that are being varied). Approval no. of label being varied: 53542/0108. Signal heading: Product name: Active constituenUs: Statement of claims: Net contents: Directions for Use Heading: Restraints: CONTRAINDICATIONS: PRECAUTIONS: Side effects: Dosage & ADMINISTRATION: PRESCRIPTION ANIMAL REMEDY + KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY U.WL EQUITY® OESTRUS CONTROL VACCINE FOR HORSES Approved Equity Oestrus Control Vaccine for Horses is prepared from an analogue of gonadotropin releasing factor (GnRF) linked to a carrier protein. It is adjuvanted with immunostimulating complex to increase the level and duration of immunity. Each mL of vaccine provides 200 11g GnRF-protein conjugate. Thiomersal 0.1 mg/mL has been added as a preservative. An aid in the control of oestrus and oestrus-related behaviour in fillies and mares not intended for breeding. Product is in 1 mL dose syringe in packs of 1, 10 or 20. Product is also in 1 OmL dose vial. DIRECTIONS FOR USE READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT Contents must be left in outer package until immediately before use. N/A Do not use this product in horses intended for breeding, or in pregnant mares. The long term effect of this product on fertility in breeding horses is poorly known and effect may be extended for multiple breeding seasons. The extent and duration of effect of booster doses of vaccine have not been studied. N/A Some swelling may develop at the site of vaccination in a small number of horses but resolves quickly, usually within a few days. The dose on all occasions is 1 mL injected intramuscularly. The most convenient site for injection is the centre of the side of the neck. Before the vaccine is injected, the proposed site of inoculation on the Baca dokumen lengkap
PRODUCT NAME: EQUITY ® OESTRUS CONTROL VACCINE FOR HORSES PAGE: 1 OF 5 THIS REVISION ISSUED: MATERIAL SAFETY DATA SHEET Issued by: Pfizer Australia Pty Ltd Phone: (02)9850 3333 SECTION 1 - IDENTIFICATION OF CHEMICAL PRODUCT AND COMPANY Pfizer Australia Pty Ltd 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9850 3399 ____________________________________ PFIZER AUSTRALIA PTY LTD A.B.N. 50 008 422 348 SUBSTANCE: Equine hormones in water solution. TRADE NAME: EQUITY ® OESTRUS CONTROL VACCINE FOR HORSES PFIZER MSDS CODE: 0814 PRODUCT USE: For use in the control of oestrus and oestrus-related behavior in fillies and mares not intended for breeding. CREATION DATE: JULY, 2004 THIS VERSION ISSUED APRIL 2010 and is valid for 5 years from this date. SECTION 2 - HAZARDS IDENTIFICATION STATEMENT OF HAZARDOUS NATURE This product is classified as: Hazardous according to the criteria of SWA Australia. Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code. RISK PHRASES: R62, R63. Possible risk of impaired fertility. Possible risk of harm to the unborn child. SAFETY PHRASES: S24/25. Avoid contact with skin and eyes. SUSDP CLASSIFICATION: S4, NZS2 ADG CLASSIFICATION: None allocated. Not a Dangerous Good. UN NUMBER: None allocated E E E M M M E E E R R R G G G E E E N N N C C C Y Y Y O O O V V V E E E R R R V V V I I I E E E W W W PHYSICAL DESCRIPTION & COLOUR : Clear liquid. Presented in disposable glass syringe containing 1 mL ODOUR: No data. MAJOR HEALTH HAZARDS: possible risk of impaired fertility, possible risk of harm to the unborn child. P P P O O O T T T E E E N N N T T T I I I A A A L L L H H H E E E A A A L L L T T T H H H E E E F F F F F F E E E C C C T T T S S S This vaccine may be immunogenic in humans and may interfere with GnRF function. This vaccine may cause atrophy of sex organs, infertility and abortion by accidental self injection. INHALATION SHORT TERM EXPOSURE: Significant inhalation exposure is considered to be unlikely. Available data indicates that this product is n Baca dokumen lengkap